BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma
• Application accepted under Priority Review designation• Application accepted into Real Time Oncology Review (RTOR) pilot program• This is BridgeBio’s second NDA...